A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy

Completed · Phase 3 · Has a placebo group

Conditions studied: Atopic Dermatitis, Atopic Hand Eczema

In brief

The purpose of this study is to test if treatment with tralokinumab is safe and efficacious in treating moderate-to-severe atopic hand eczema. This will be judged by a range of assessments that rate the severity and extent of atopic hand eczema and its symptoms, as well as general health status and quality of life. The trial will last for up to 40 weeks for each participant. There will be up to 15 visits for each participant, 3 of which will be conducted by phone. The first part of the trial is called a screening period and will last up to 4 weeks. For the first 16 weeks after screening, trial participants will receive either tralokinumab or dummy injections every two weeks. After the first 16 weeks, all trial participants will receive tralokinumab injections every two weeks for 16 weeks. The last part of the trial is a period of 4 weeks after the end of treatment period, where trial participants will not receive tralokinumab but are monitored for safety.

Key facts

Study ID: NCT05958407
Run by: LEO Pharma
People needed: 235
Starts: 2023-08-28
Expected to finish: 2025-09-22
Last updated by the study team: 2026-08-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Age 18 years or above at screening
Diagnosis of atopic dermatitis (AD) as by the Hanifin and Rajka (1980) criteria for AD
History of AD for ≥1 year
Presence of atopic hand eczema (AHE) that has persisted for more than 3 months or returned twice or more within the last 12 months, with avoidance of any known and relevant irritants and allergens
AD involvement of at least one body location other than the hands and wrists at screening
An Investigator's Global Assessment AHE score of 3 or 4 (moderate to severe) at screening and baseline
A HESD itch score (weekly average) of ≥4 at baseline
Subjects who have a documented recent history (within 12 months before the screening visit) of inadequate response to treatment of AHE with topical prescription medications or for whom topical treatments are otherwise medically inadvisable (e.g., due to important side effects or safety risks)

You may not qualify if…

Subjects must not enter the trial if they have active subtypes of hand eczema other than AHE that are considered to be the predominant cause of the current hand eczema including:
Active irritant contact dermatitis
Active allergic contact dermatitis
Active protein contact dermatitis/contact urticaria
Active hyperkeratotic hand eczema
Active vesicular hand eczema (pompholyx)
Active dermatologic conditions that may confound the diagnosis of AD or AHE, or that would interfere with the assessment of treatment
Use of tanning beds or phototherapy (e.g., UVB, UVA1, PUVA), or Grenz ray therapy on the hands or wrists within 28 days prior to baseline or use of bleach baths on the hands or wrists within 7 days prior to baseline
Treatment with systemic immunosuppressive/immunomodulating drugs and/or systemic corticosteroids within 28 days prior to baseline
Treatment with topical corticosteroids, topical calcineurin inhibitors, topical phosphodiesterase 4 inhibitors, or topical Janus kinase inhibitors within 7 days prior to baseline
Receipt of any marketed biological therapy (i.e. immunoglobulin, anti immunoglobulin E) including dupilumab or investigational biologic agents 3 to 6 months prior to baseline

Where it is running

LEO Pharma Investigational Site — Fort Smith, Arkansas, United States
LEO Pharma Investigational Site — Fountain Valley, California, United States
LEO Pharma Investigational Site — Los Angeles, California, United States
LEO Pharma Investigational Site — Sacramento, California, United States
LEO Pharma Investigational Site — Farmington, Connecticut, United States
LEO Pharma Investigational Site — Hialeah, Florida, United States
LEO Pharma Investigational Site — Plainfield, Indiana, United States
LEO Pharma Investigational Site — Louisville, Kentucky, United States
LEO Pharma Investigational Site — New Orleans, Louisiana, United States
LEO Pharma Investigational Site — Bangor, Maine, United States
LEO Pharma Investigational Site — Caledonia, Michigan, United States
LEO Pharma Investigational Site — Detroit, Michigan, United States
LEO Pharma Investigational Site — Portsmouth, New Hampshire, United States
LEO Pharma Investigational Site — Cortland, New York, United States
LEO Pharma Investigational Site — New York, New York, United States
LEO Pharma Investigational Site — Portland, Oregon, United States
LEO Pharma Investigational Site — Portland, Oregon, United States
LEO Pharma Investigational Site — Nashville, Tennessee, United States
LEO Pharma Investigational Site — Dallas, Texas, United States
LEO Pharma Investigational Site — Frisco, Texas, United States
LEO Pharma Investigational Site — San Antonio, Texas, United States
LEO Pharma Investigational Site — Webster, Texas, United States
LEO Pharma Investigational Site — Brussels, Belgium
LEO Pharma Investigational Site — Edegem, Belgium
LEO Pharma Investigational Site — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.